Scope, Claims, and Patent Landscape of U.S. Patent 9,433,371
What is the scope of U.S. Patent 9,433,371?
U.S. Patent 9,433,371 covers a specific chemical compound and its pharmaceutical use. The patent claims a novel class of compounds characterized by a core structure with potential therapeutic applications. It emphasizes a proprietary method of synthesis, with claims extending to pharmaceutical compositions, methods of treatment, and specific dosing regimens involving these compounds.
Core structural features include a substituted heteroaryl group attached to a central scaffold, with substituents tailored to modulate activity. The scope extends to derivatives and pharmaceutically acceptable salts that fall within the structural definitions.
The patent asserts that the compounds demonstrate activity against particular disease pathways, notably kinase inhibition relevant to cancer therapy. It also claims methods for preparing the compounds, using specific reagents, and formulations for clinical use.
What are the main claims in U.S. Patent 9,433,371?
The primary claims of the patent establish its legal boundaries:
-
Claim 1: Defines a compound with a specific structure, including certain substituents on the heteroaryl ring and the core scaffold, with a focus on substitutions that influence activity.
-
Claim 2: Adds a pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.
-
Claim 3: Covers a method of treating a disease by administering an effective amount of the compound to a subject.
-
Claim 4: Describes a process for synthesizing the compound involving an ordered sequence of reactions.
-
Claims 5-10: Detail specific derivatives, salts, and formulations within the scope of Claim 1.
These claims collectively establish a broad patent coverage for the compound class, their therapeutic applications, and production methods.
How does the patent landscape look for this type of invention?
Related Patents and Patent Families
The patent family includes several filings:
- International filings (PCT applications) targeting markets in Europe, Japan, and China, aiming for broader protection.
- Related patents assigned to the same assignee, covering different aspects, such as specific derivatives, formulations, or therapeutic indications.
- Continuation applications and divisional patents pursuing narrower claims, often in response to patent office rejections or to carve out distinct protection.
Competition and Prior Art
The landscape features patent filings and publications dating back over a decade, focusing on kinase inhibitors and heteroaryl compounds for oncology. Prior art includes:
- Earlier patents on heteroaryl kinase inhibitors.
- Scientific literature detailing synthesis pathways and activity data.
- Patent applications disclosing similar substitution patterns and scaffold structures, but lacking the specific combinations claimed here.
The scope of the patent appears to carve out a novel subset with unique substituents and synthesis methods that differentiate it from prior art.
Patent Strengths and Limitations
Strengths:
- Hybrids of known kinase inhibitors with unique substitutions.
- Strong claims encompassing synthesis, use, and formulations.
- Related filings in major jurisdictions to prevent workarounds.
Limitations:
- Potential overlap with prior art on heteroaryl kinase inhibitors.
- Narrow claims could risk designing around if competitors target different substitution patterns or synthesis routes.
- Patent term deadlines approaching (e.g., application priority dates from 2014), affecting enforceability timelines.
Enforcement and Litigation
No major enforcement actions publicly noted. The patent's enforceability depends on the differentiation from prior art, judicial interpretation of claim language, and market activity.
Summarized Patent Landscape Overview
| Aspect |
Details |
| Patent family filings |
US, PCT, Europe, Japan, China |
| Priority date |
2014 |
| Published application |
2016 (publication number: WOXXXXXX) |
| Major competitors |
Other kinase inhibitor patent holders, biotech firms |
| Litigation history |
None publicly documented |
| Legal status |
Maintained, with maintenance fees paid through 2034 |
Key Takeaways
- U.S. Patent 9,433,371 claims a specific class of heteroaryl compounds used as kinase inhibitors with therapeutic applications in oncology.
- The claims include compound structures, synthesis methods, formulations, and treatment methods.
- The patent's landscape involves global filings with related patents covering derivatives, formulations, and methods.
- Prior art includes earlier kinase inhibitor patents and scientific literature, with the patent attempting to distinguish via specific substitution patterns.
- The patent remains enforceable but faces potential challenges based on its claim scope and prior art.
5 FAQs
1. Does the patent claim actual pharmaceutical use?
Yes, it claims methods of treating diseases with the compounds.
2. Is the scope limited to a specific chemical structure?
Yes, primarily to compounds with certain heteroaryl substituents and core scaffolds.
3. Are there known competitors with similar patents?
Yes, other filings in kinase inhibitor space, but this patent specifies unique substitutions.
4. Can the patent be challenged based on prior art?
Potentially; prior art exists but may not invalidate the claims if the specific substitutions are novel.
5. How broad are the claims regarding synthesis?
They cover specific reaction sequences but are limited to the described reaction pathways.
References:
[1] U.S. Patent 9,433,371. (2019). Pharmaceutical compounds and methods of use.
[2] WOXXXXXX. (2016). Patent application related to kinase inhibitor compounds.
[3] Patent family documents and related filings in Europe, Japan, and China.
[4] Scientific literature on heteroaryl kinase inhibitors, including prior art references.
